Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mammoth Biosciences
Mammoth Biosciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Presentation to take place at 7.30 am PT on Thursday, January 15, 2026 Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference.
Mammoth Biosciences to Present Preclinical Data on MB-111 at the European Society of Gene & Cell Therapy 32nd Annual Congress
MB-111 is a potential first-in-class, single-dose in vivo CRISPR gene editing therapy for persistent chylomicronemia Oral presentation highlights safe, robust, and durable reduction of apoC-III and triglycerides by MB-111 in animal models Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation in vivo CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical data on its first clinical development...
Mammoth Biosciences Announces Nomination of MB-111 as First Development Candidate and Appoints Genetic Medicines Veteran Bob D. Brown to Board of Directors | Financial News | myMotherLode.com
MB-111 is a potential first-in-class in vivo ultracompact CRISPR therapy for Familial Chylomicronemia Syndrome and Severe Hypertriglyceridemia Dr. Brown brings deep expertise in nucleic acid drug development as Mammoth advances its lead program, MB-111, to IND-enabling stage and continues to build a leading company in genetic medicines Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time...
Mammoth Biosciences to Present Preclinical Data on In Vivo Gene Editing of Skeletal Muscle in Non-Human Primates with an Ultracompact CRISPR System at ASGCT 2025 | Financial News | myMotherLode.com
Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced that Renan Sper, DVM, Ph.D., principal scientist, preclinical therapeutics at Mammoth, will present new preclinical data at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, May 13-17, 2025.
Mammoth Biosciences Announces New Results on NanoCas - the First Efficient Ultracompact Extrahepatic Gene Editor
New research shows potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical research, published on the preprint server bioRxiv, that establishes proof-of-concept of NanoCas™, the first ultracompact CRISPR...
Mammoth Biosciences Announces New Results on NanoCas - the First Efficient Ultracompact Extrahepatic Gene Editor
www.cablinginstall.comis using a security service for protection against online attacks. The service requires full JavaScript support in order to view this website. Please enable JavaScript on your browser and try again.
Mammoth Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Presentation to take place at 11 am PT on Thursday, January 16, 2025 Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene-editing platform to create potential one-time curative therapies, today announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mammoth
Contact Mammoth, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack